Home » Newsletters » BioWorld

BioWorld

Jan. 14, 1993

View Archived Issues

QUIDEL ACQUIRES DISTRIBUTOR

GYNEX LICENSES REGIMEN FOR ORAL CONTRACEPTIVES

ARGUS FILES FOR OFFERING

NEW CENTER FOR 'NATURAL' MEDICINES

CELLPRO FILES FOR OFFERING

AMYLIN PLANS PHASE II FOR DIABETES DRUG

BIOMATRIX AMENDS KABI PACT

BAXTER BEGINS BLOOD SUBSTITUTE TRIALS

SERAGEN REPORTS RESPONSE TO IL-2

REGENERON BEGINS PHASE II TRIALS FOR ALS

AIDS DRUG ENTERS PHASE II/III

PMA REPORTS FLOOD OF INDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...